THE RESEARCH OF DR. YOUN KIM
Youn H. Kim, M.D., Stanford University, Stanford, California
Youn H. Kim, M.D. is the recipient of the first Joanne and Peter Haas Jr. Professorship for Cutaneous Lymphoma Research at Stanford University School of Medicine. She is a Professor of Dermatology and a member of the Stanford Cancer Center. Dr. Kim is the Director of the Multidisciplinary Cutaneous Lymphoma Clinic and Research Program at Stanford and the Co-Director of the Lymphoma Research Programs at Stanford Cancer Center. Dr. Kim is a member of the Non-Hodgkin’s Lymphoma Panel of the National Comprehensive Cancer Network (NCCN). She serves on the Board of Directors of the US Cutaneous Lymphoma Consortium and recently served as the President of the International Society for Cutaneous Lymphomas. She is an elected member of the American Dermatologic Association, member of the American Society of Hematology, the American Academy of Dermatology, and the Society for Investigative Dermatology.
Dr. Kim has published extensively to advance the field of cutaneous lymphoma. Her clinical research has focused in 3 key areas: (1) clinical outcome studies in patients with cutaneous lymphoma, (2) therapeutic trials (industry and investigator-initiated) and translational research involving new therapy development in cutaneous lymphoma, and (3) furthering our understanding of molecular pathogenesis and gene signatures reflective of prognosis and response to therapy. Stanford houses one of the largest single-center longitudinal databases in mycosis fungoides (MF) and Sézary syndrome (SS). Stanford’s Multidisciplinary Cutaneous Lymphoma Clinic is a major national and international referral center and keeps one of the largest single-center longitudinal databases in cutaneous lymphomas. Dr. Kim and her multidisciplinary colleagues at Stanford published key staging and outcomes data that are used as the basis in staging, prognostication, and therapy stratification in MF/SS including those in the revised international consensus documents for staging in MF/SS, other cutaneous lymphomas, and in the NCCN practice guidelines. Dr. Kim has served as the PI or co-investigator in multiple pivotal clinical trials that have been critical in the discovery and development of newer therapies in cutaneous T-cell lymphoma.
Youn H. Kim, M.D. is the recipient of the first Joanne and Peter Haas Jr. Professorship for Cutaneous Lymphoma Research at Stanford University School of Medicine. She is a Professor of Dermatology and a member of the Stanford Cancer Center. Dr. Kim is the Director of the Multidisciplinary Cutaneous Lymphoma Clinic and Research Program at Stanford and the Co-Director of the Lymphoma Research Programs at Stanford Cancer Center. Dr. Kim is a member of the Non-Hodgkin’s Lymphoma Panel of the National Comprehensive Cancer Network (NCCN). She serves on the Board of Directors of the US Cutaneous Lymphoma Consortium and recently served as the President of the International Society for Cutaneous Lymphomas. She is an elected member of the American Dermatologic Association, member of the American Society of Hematology, the American Academy of Dermatology, and the Society for Investigative Dermatology.
Dr. Kim has published extensively to advance the field of cutaneous lymphoma. Her clinical research has focused in 3 key areas: (1) clinical outcome studies in patients with cutaneous lymphoma, (2) therapeutic trials (industry and investigator-initiated) and translational research involving new therapy development in cutaneous lymphoma, and (3) furthering our understanding of molecular pathogenesis and gene signatures reflective of prognosis and response to therapy. Stanford houses one of the largest single-center longitudinal databases in mycosis fungoides (MF) and Sézary syndrome (SS). Stanford’s Multidisciplinary Cutaneous Lymphoma Clinic is a major national and international referral center and keeps one of the largest single-center longitudinal databases in cutaneous lymphomas. Dr. Kim and her multidisciplinary colleagues at Stanford published key staging and outcomes data that are used as the basis in staging, prognostication, and therapy stratification in MF/SS including those in the revised international consensus documents for staging in MF/SS, other cutaneous lymphomas, and in the NCCN practice guidelines. Dr. Kim has served as the PI or co-investigator in multiple pivotal clinical trials that have been critical in the discovery and development of newer therapies in cutaneous T-cell lymphoma.